The Supreme Court made it easier on Wednesday for U.S. manufacturers to infringe patents held by competitors by manufacturing all but one of the infringing components abroad. The practical consequences could be significant, as could the court’s apparent view that the key U.S. appeals court for patent cases has been too sympathetic to patent holders.
Second-quarter earnings season has been going for more than a week, and we’ve had a chance to hear from all four of the biggest companies in biotech as measured by sales, market valuation and clout.